Daiichi Sankyo and German research institute BioMed X have agreed a new partnership to advance the development of bi- and multi-specific biologics for treating solid tumours. The new project, entitled ‘New Strategies for Targeting of Solid Tumours with Multi-Specific Biologics (MTT; Multi-Specific Targeting of Tumours)’, will be hosted at the BioMed X Institute in Heidelberg. […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
